John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics
June 08 2010 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John
G. McHutchison, MD, will join the company as Senior Vice President,
Liver Disease Therapeutics. In this position, Dr. McHutchison will
report to Norbert W. Bischofberger, PhD, Executive Vice President,
Research and Development and Chief Scientific Officer and will have
responsibility for Gilead’s research and development efforts
supporting the company’s programs in liver disease, including
hepatitis C.
Dr. McHutchison will also join Gilead’s Executive Committee.
“John is recognized internationally as one of the leading
experts in gastroenterology and hepatology, and I am very pleased
to welcome him to the Gilead team,” said Dr. Bischofberger. “John’s
appointment as Senior Vice President is indicative of the strong
commitment we have to the therapeutic category of liver disease.
His extensive clinical and translational research experience in
this area will be of great value as we work to advance promising
pipeline programs in hepatitis C and further characterize the
profile of our commercial products in hepatitis B.”
Dr. McHutchison joins Gilead from Duke University Medical
Center, where he most recently served as Associate Director of the
Duke Clinical Research Institute and Director of the GI/Hepatology
Research Program. He also held the positions of Professor of
Medicine in the Division of Gastroenterology at Duke University
Medical Center, Co-Director of the Duke Clinical and Translational
Science Award and Director of the Duke Clinical Research Unit.
“The strength of Gilead’s scientific leadership and the unique
opportunity to help shape future therapeutic possibilities for many
patients with liver disease led to my keen interest in the
company,” said Dr. McHutchison. “After meeting with the Gilead
team, I am very enthusiastic about the company’s potential to
advance promising treatments for patients with hepatitis C and
other liver diseases – areas where there remains a large unmet
medical need.”
Dr. McHutchison received bachelor of medicine and bachelor of
surgery degrees from the University of Melbourne, Australia, and
completed his residency in internal medicine and a fellowship in
gastroenterology at the Royal Melbourne Hospital. Dr. McHutchison
is also a member of the Royal Australasian College of Physicians.
He is a member of several scientific advisory boards, serves on the
editorial boards of numerous scientific journals and has published
more than 300 peer-reviewed articles and abstracts.
About Gilead
Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
For more information on Gilead,
please call the Gilead Public Affairs Department at1-800-GILEAD-5
(1-800-445-3235) or visit www.gilead.com.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024